Acasti Pharma Inc (ACST)
$2.69
Insights on Acasti Pharma Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 58.5% return, outperforming this stock by 68.4%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 232.5% return, outperforming this stock by 321.4%
Performance
- $2.67$2.69$2.69
0.74%
Downside
Day's Volatility :0.89%
Upside
0.14%
- $1.72$3.84$2.69
36.06%
Downside
52 Weeks Volatility :55.21%
Upside
29.95%
Returns
| Period | Acasti Pharma Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -18.87% | 0.0% |
6 Months | 30.62% | 0.0% |
1 Year | -9.9% | 0.0% |
3 Years | -88.65% | -20.1% |
Highlights
Market Capitalization | 25.4M |
Book Value | $6.88 |
Earnings Per Share (EPS) | -5.68 |
PEG Ratio | 0.0 |
Wall Street Target Price | 5.99 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -7.92% |
Return On Equity TTM | -48.05% |
Revenue TTM | 115.0K |
Revenue Per Share TTM | 0.01 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 120.0K |
EBITDA | -12.2M |
Diluted Eps TTM | -5.68 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.45 |
EPS Estimate Next Year | -1.12 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 122.68%
Technicals Summary
Sell
Neutral
Buy
Acasti Pharma Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Acasti Pharma Inc | -4.21% | 30.62% | -9.9% | -88.65% | -93.68% |
 Moderna, Inc. | 37.56% | 83.82% | 13.37% | -12.47% | 553.14% |
 Regeneron Pharmaceuticals, Inc. | 10.42% | 24.29% | 32.26% | 98.6% | 210.52% |
 Novo Nordisk A/s | 7.9% | 30.89% | 58.53% | 230.87% | 458.51% |
 Vertex Pharmaceuticals Incorporated | 10.52% | 25.13% | 30.01% | 109.26% | 156.43% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Acasti Pharma Inc | NA | NA | 0.0 | -1.45 | -0.48 | -0.08 | NA | 6.88 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.46 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 29.16 | 29.16 | 1.46 | 44.2 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 45.83 | 45.83 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 28.9 | 28.9 | 0.53 | 17.11 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Acasti Pharma Inc | Buy | $25.4M | -93.68% | NA | 0.0% |
Moderna, Inc. | Buy | $54.0B | 553.14% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.8B | 210.52% | 29.16 | 29.45% |
Novo Nordisk A/s | Buy | $592.1B | 458.51% | 45.83 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $115.1B | 156.43% | 28.9 | 39.46% |
Institutional Holdings
Bank of America Corp
5.26%ADAR1 Capital Management LLC
0.37%Royal Bank of Canada
0.34%UBS Group AG
0.06%Morgan Stanley - Brokerage Accounts
0.02%
Company Information
acasti pharma, inc., a subsiduary of neptune technologies & bioressources, is a quebec-based biopharmaceutical dedicated in advancing a proprietary portfolio based on marine phospholipids. our products can be used in prescription, medical food and over-the-counter applications, either as a stand-alone, or, as a fixed-dose combination to exisitng productrs, for the prevention and treatment of cardiometabolic disorders.
Organization | Acasti Pharma Inc |
Employees | 0 |
CEO | Mr. Prashant Kohli |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$2.69
-1.47%
Keyarch Acquisition Corp
$2.69
-1.47%
Connexa Sports Technologies Inc
$2.69
-1.47%
Us Value Etf
$2.69
-1.47%
First Wave Biopharma Inc
$2.69
-1.47%
Global X Msci Next Emerging
$2.69
-1.47%
Fat Projects Acquisition Corp
$2.69
-1.47%
Ishares Intl Div Growth Etf
$2.69
-1.47%
Corsair Gaming, Inc.
$2.69
-1.47%